Afatinib has been tested in a clinical trial against HER2 positive breast cancer cells and can be used as a TKI-PET tracer23, further underscoring the links between the metabolic status of tumour cells and their response to PPP inhibition. The gene discussed is ERBB2; the disease is breast carcinoma.